Behzad Aghazadeh, a Director and 10%+ owner of Scribe Therapeutics, Inc. (SCTX), purchased 7,905 shares of the gene-editing company on July 28, 2026, paying $18.25 per share for a total outlay of $144,266.25. The shares were acquired on the open market, meaning Aghazadeh used personal funds rather than receiving the stock through options or other compensation. Following the purchase, Aghazadeh’s indirect holdings, held through a trust or entity, stand at 3,088,888 shares.
Anyone tracking insider buying and selling closely will notice this filing does not stand alone. It’s the third open-market purchase tied to Aghazadeh in a five-day window between July 24 and July 28, 2026. Combined, the three transactions total $36,259,761 in purchases at Scribe Therapeutics, a figure that dwarfs the value of the July 28 filing on its own.
Why the Pattern Matters More Than One Filing
A single open-market purchase by an insider can reflect any number of personal financial decisions and often tells an outside observer little on its own. A cluster of purchases from the same insider, spread across multiple days and totaling tens of millions of dollars, is a different kind of signal. Our classification tags this filing as a ‘cluster buy’ precisely because it fits a repeated, sustained pattern rather than a one-off trade.
Academic research on insider trading has found that clustered buying, multiple insiders or repeated purchases by the same insider within a short window, tends to correlate with periods of stronger subsequent stock performance compared to isolated purchases. That said, this is historical, statistical context about insider trading patterns broadly. It is not a statement about what will happen to SCTX shares, and this article is not suggesting any action be taken based on the filing.
Scribe Therapeutics is a private-to-public-adjacent biotech name in the gene-editing space, and insider ownership concentrated in a director or 10%+ owner is common at companies where founders or early backers retain large, often indirect, equity stakes. The fact that Aghazadeh’s post-transaction holdings are held indirectly suggests the shares sit inside a trust, fund, or affiliated entity rather than a personal brokerage account, a detail worth noting for anyone trying to map out who actually controls the underlying stake.
For readers who track insider buying and selling on platforms and want to understand how common filings like this actually are, the SEC’s Form 4 disclosure system requires insiders to report transactions within two business days, which is how a pattern like this becomes visible in near real time rather than months later.
Source: original SEC Form 4 filing.